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Homoarginine and inhibition of 
human arginase activity: kinetic 
characterization and biological 
relevance
S. Tommasi1, D. J. Elliot1, M. Da Boit2, S. R. Gray  3, B. C. Lewis  1,4 & A. A. Mangoni1
The inhibition of arginase, resulting in higher arginine (ARG) availability for nitric oxide synthesis, may 
account for the putative protective effect of homoarginine (HOMOARG) against atherosclerosis and 
cardiovascular disease. However, uncertainty exists regarding the significance of HOMOARG-induced 
arginase inhibition in vivo. A novel UPLC-MS method, measuring the conversion of ARG to ornithine 
(ORN), was developed to determine arginase 1 and arginase 2 inhibition by HOMOARG, lysine (LYS), 
proline (PRO), agmatine (AG), asymmetric dimethylarginine (ADMA), symmetric dimethylarginine 
(SDMA), and NG-Monomethyl-L-arginine (L-NMMA). Plasma HOMOARG, ARG and ORN concentrations 
were further measured in 50 healthy older adults >65 years (27 males and 23 females). HOMOARG 
inhibited arginase 1 with IC50 and Ki values of 8.14 ± 0.52 mM and 6.1 ± 0.50 mM, and arginase 2 
with IC50 and Ki values of 2.52 ± 0.01 mM and 1.73 ± 0.10 mM, respectively. Both arginase isoforms 
retained 90% activity vs. control when physiological HOMOARG concentrations (1–10 µM) were used. 
In partial correlation analysis, plasma HOMOARG was not associated with ARG (P = 0.38) or ARG/
ORN ratio (P = 0.73) in older adults. Our results suggest that arginase inhibition is unlikely to play a 
significant role in the reported cardio-protective effects of HOMOARG.
Recent human studies have reported an inverse correlation between the serum and plasma concentrations of 
homoarginine (HOMOARG), a basic amino acid and analogue of arginine (ARG), and cardiovascular risk. 
Chemically, HOMOARG differs from ARG by a single methylene-group extension of the side-chain. Clinically, 
low serum concentrations of HOMOARG are associated with renal dysfunction, increased cardiovascular risk 
and mortality1–7. High serum HOMOARG concentrations have also been associated with enhanced endothelial 
function in the mother during pregnancy8. It has been speculated that HOMOARG exerts protective effects in the 
cardiovascular system via inhibition of the enzyme arginase. Arginase is an enzyme of the urea cycle that catalyses 
the conversion of ARG to ornithine (ORN) and urea, thus playing a key role in nitrogen metabolism. There are 
two arginase isoforms in mammals, arginase 1 and arginase 2, with different tissue and cellular distributions. The 
role of arginase 1 is particularly important in liver and blood cells, while arginase 2 is a key enzyme in the kidney9. 
HOMOARG-mediated arginase inhibition would lead to the accumulation of the substrate ARG, and a conse-
quent increase in nitric oxide (NO) synthesis by the NO synthase enzymes1,7. The latter would provide salutary 
effects in terms of vascular homeostasis and atheroprotection.
Several studies have previously investigated arginase 1 and arginase 2 enzyme kinetics, identified alternative 
substrates, and characterised the inhibitory potential of endogenous compounds10–19. However, the results of 
studies investigating the effect of HOMOARG on arginase activity have been contradictory. Both Reczkowski 
and Ash11 and Hunter and Downs14 reported that HOMOARG is an alternative substrate for arginase 1. However, 
other studies have shown that HOMOARG is an arginase 1 inhibitor, without substrate activity10,12,20. Similarly, 
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HOMOARG was found to be an inhibitor, but not a substrate, of arginase 217. More recently, Michel has repro-
posed HOMOARG as a potential arginase substrate19.
In view of the conflicting results of previous studies, clarification of the role of HOMOARG in modulating 
the activity of the arginase isoforms 1 and 2 will have significant biological and clinical relevance. We sought to 
address this issue by studying the effects of HOMOARG, in addition to other endogenous molecules such as 
lysine (LYS), proline (PRO), agmatine (AG), asymmetric dimethylarginine (ADMA), symmetric dimethylargi-
nine (SDMA), and NG-Monomethyl-L-arginine (L-NMMA), on arginase 1 and 2 activity. LYS was selected as a 
positive control for arginase inhibition, as it is the prototypic arginase inhibitor10–15. In contrast, ADMA, SDMA, 
L-NMMA, important modulators of the NO pathway together with ARG and HOMOARG, have failed to show 
inhibitory potential when incubated with arginase, and were selected as negative controls18,19. Additionally, PRO 
and AG, previously described as poor arginase inhibitors10,11,14–17,21, were included in this study. The concentra-
tion range used for the compounds tested was chosen in order to cover their physiological concentrations found 
in plasma and up to 10,000-fold their circulating concentrations.
Our in vitro experimentation utilised a highly sensitive and specific UPLC-MS method to measure arginase 
activity, from an expression system that better represents physiological conditions. Specifically, we incubated our 
samples in phosphate buffer, abundant in living organism, instead of the commonly reported tris-buffer, and we 
used un-purified cell lysate as the source of protein. Lysates were obtained from cells overexpressing arginase 1 or 
arginase 2 in the absence of EDTA to maintain the cellular concentrations of divalent ions, removing the need for 
manganese supplementation. We also investigated the inhibitory potential of HOMOARG on arginase activity 
in vivo by assessing the associations between HOMOARG concentrations and the ARG/ORN ratio in a cohort of 
healthy older adults.
Results
Cloning and expression of arginase 1 and arginase 2. HEK293T cells stably expressing recombinant 
human arginase 1 or arginase 2 were analysed using immunological detection. Both arginase enzymes were 
observed at an apparent molecular weight of 40 kDa (Fig. 1 and Supplementary File) as expected according to 
the antibodies manufacturer. Immunoreactive bands were not observed when probing arginase 1 lysates with 
anti-arginase 2 antibody, and vice versa.
UPLC-MS analysis of ORN. Extracted ion chromatograms (EICs) were obtained with a mass window of 
0.02 Da from total ion chromatogram (TIC) using m/z of 133.11 and 139.15 corresponding to the parent ions 
([M + H]+) of ORN and ORN-d6 respectively (Fig. 2). Calibration curves were obtained by plotting the peak area 
ratio ORN to internal standard versus the standard concentration.
ORN quantification was linear between 0 and 200 µM (Fig. 3), with a limit of detection of 3 and 0.1 µM for 
arginase 1 and arginase 2 assays, respectively, and a limit of quantitation of 10 and 0.3 µM for arginase 1 and argin-
ase 2, respectively. The limit of detection was calculated as the ORN concentration corresponding to 3:1 signal 
to noise ratio, whereas the limit of quantitation was calculated as the ORN concentration corresponding to 10:1 
signal to noise ratio.
Characterisation of arginase 1 and arginase 2 kinetic parameters. Linear conditions for the con-
version of ARG into ORN were observed up to 20-min time for arginase 1 and up to 40-min time for arginase 2 
(Fig. 3). ORN conversion was not linear across the range of protein concentrations investigated, with the same 
trend observed for both arginase 1 and arginase 2 (Fig. 3). Reproducibility of ORN formation was assessed for 6 
replicates with substrate concentrations of 1 and 10 mM for both arginase 1 and arginase 2 (Table 1).
As the rate of arginase 1-mediated ORN formation from ARG was 20% higher in absence of manganese sup-
plementation, manganese supplementation was not used in our experiments. Omission of manganese did not 
influence the shape of the rate-concentration curve (data not shown) and hence it was not expected to influence 
the kinetic parameters Km and Ki.
The kinetic behaviour of the arginase 1 expression system was characterised at 0.05 mg/mL protein and 
10-min incubation time. The kinetic parameters were derived from non-linear least squares fitting of experi-
mental data for ARG conversion to ORN. For arginase 1, mean Km and Vmax values were 3.3 ± 0.2 mM and 34 ± 1 
nmol·min−1·mg−1, respectively. Characterisation of ARG conversion to ORN by arginase 2 was performed at 
Figure 1. Expression of recombinant arginase 1 and arginase 2 in HEK293T cell lysate as shown by 
representative western blots performed using (A) anti-arginase 1, (B) anti-arginase 2, and (C) anti-FLAG 
primary antibodies, respectively. Each blot shows: molecular markers (lane 1), untransfected HEK293T cell 
lysate (lane 2, 100 µg), arginase 1 lysate (lane 3, 30 µg), and arginase 2 lysate (lane 4, 30 µg).
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0.1 mg/mL protein with a 20-min incubation time. Mean Km and Vmax values were 1.9 ± 0.1 mM and 883 ± 16 
pmol·min−1·mg−1, respectively.
Derived Km and Vmax values are reported in Table 2 and Fig. 4.
Arginase 1 and arginase 2 inhibition. Concentration-dependent effects. Data represent the mean of 
two singlicate experiments. A concentration-dependent inhibition of arginase 1 by LYS and HOMOARG was 
observed at both substrate concentrations of 3 mM (Km) and 100 µM (physiological concentration of ARG in 
plasma). LYS, at concentrations of 1 and 10 mM, showed 39 and 78% inhibition of arginase 1 activity at Km 
concentration of the substrate, and 44 and 81% inhibition at physiological ARG concentrations. When the exper-
iments were performed at Km, HOMOARG, at a concentration of 1 mM, inhibited arginase 1 activity by 14%, 
whereas a concentration of 10 mM resulted in 50% inhibition of the enzyme. At 100 µM ARG concentration, 
arginase 1 inhibition by 1 and 10 mM HOMOARG was 30 and 76%, respectively. Notably, no significant inhib-
itory effects of arginase 1 activity were observed with physiological concentrations of LYS, 100–1000 µM22, and 
HOMOARG, 1–10 µM23, respectively. Conversely, at the concentrations tested, PRO, AG, ADMA, L-NMMA and 
Figure 2. Representative chromatograms for ORN (B,D,F and H) and internal standard ORN–d6 (A,C,E and 
G) extracted at 133.112 and 139.148 Da corresponding to molecular ion of ORN and ORN–d6 respectively. 
Chromatograms are shown for ORN in arginase 1 calibrator 0 (C and D) and calibrator 4 (A and B), comprising 
0.05 mg/mL arginase 1 HEK293T lysate, 0.05 M phosphate buffer, 3 mM ARG, 10 µL of 1200 µM ORN–d6 and 
0 µM ORN (D) or 200 µM ORN (B). The corresponding internal standard chromatograms are shown in panels 
C and A. Similarly, chromatograms are shown for ORN in arginase 2 calibrator 0 (G and H) and calibrator 5 
(E and F), comprising 0.1 mg/mL arginase 2 HEK293T lysate, 0.05 M phosphate buffer, 2 mM ARG, 10 µL of 
300 µM ORN–d6 and 0 µM ORN (H) or 50 µM ORN (F). The corresponding internal standard chromatograms 
are shown in panels G and E. The small peak observed for ORN in calibrator 0 (D and H) arises from very low 
concentrations of endogenous ORN present in the HEK293T lysate.
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Figure 3. Calibration curves, time and protein plots for arginase 1 (A,C and E) and arginase 2 (B,D,F). ORN 
calibration curves (A and B) were constructed by plotting the peak area ratio ORN to ORN-d6 versus the ORN 
concentration. Each data point represents the mean of three injections. Error bars represent the standard error 
of the mean. Time (C and D) and protein (E and F) data were collected in singlicate.
Isoenzyme ARG/mM ORN/µM % CV
Arginase 1 1 56.4 6.3
Arginase 1 10 153.5 2.9
Arginase 2 1 11.7 4.1
Arginase 2 10 21.1 4.2
Table 1. Reproducibility of ORN formation.
Enzyme Parameter Expt 1 Expt 2 Expt 3 Mean
Arginase 1
Km (mM) ± SE 3.4 ± 0.4 3.8 ± 0.2 3.5 ± 0.2 3.3 ± 0.2
95% confidence interval Km 2.6–4.2 3.4–4.2 3.0–4.0 2.9–3.8
Vmax (nmol·min−1·mg−1) ± SE 37 ± 1 32 ± 1 35 ± 1 34 ± 1
95% confidence interval Vmax 34–40 31–33 33–36 32–35
F statistic 1360 3194 3419 4346
R-squared 0.9927 0.9969 0.9971 0.9977
SE of fit 0.8875 0.4901 0.5173 0.4581
Arginase 2
Km (mM) ± SE 2.4 ± 0.1 1.7 ± 0.1 1.8 ± 0.1 1.9 ± 0.1
95% confidence interval Km 2.2–2.5 1.5–1.9 1.7–1.9 1.6–2.2
Vmax (pmol·min−1·mg−1) ± SE 984 ± 8 837 ± 12 834 ± 5 883 ± 16
95% confidence interval Vmax 967–1002 810–864 822–846 848–918
F statistic 1833 3390 379 2662
R-squared 0.9946 0.9971 0.9743 0.9963
SE of fit 20.5065 13.5723 38.162 15.5307
Table 2. Derived kinetic parameters for the conversion of ARG to ORN by arginase 1 and arginase 2. 
Kinetic constants (Km, Vmax) for ORN formation were derived from fitting the Michaelis-Menten equation to 
experimental data using the nonlinear curve fitting software EnzFitter. SE: standard error.
www.nature.com/scientificreports/
5SCIentIFIC REpoRTS |  (2018) 8:3697  | DOI:10.1038/s41598-018-22099-x
SDMA were poor arginase 1 inhibitors at both ARG concentrations (Table 3). An analogous trend emerged for 
arginase 2 inhibition by LYS and HOMOARG, while PRO, AG and methylated arginines were confirmed as poor 
inhibitors of each arginase isoenzymes. Experiments performed using arginase 2 and 2 mM ARG resulted in 18 
and 94% inhibition by HOMOARG at the concentration of 1 and 10 mM, and 42 and 67% inhibition by LYS at 
1 and 10 mM. At 100 µM ARG concentration, the conversion of ARG to ORN by arginase 2 was inhibited by 47 
and 88% in the presence of 1 and 10 mM HOMOARG, and there was 44 and 88% inhibition by 1 and 10 mM LYS 
(Table 3). Similarly to arginase 1, no significant inhibition of arginase 2 was observed at physiological LYS and 
HOMOARG concentrations.
The inhibitory potential was fully characterised for compounds showing 50% inhibition or more at the highest 
concentration used in these preliminary experiments, thus further characterisation was undertaken for LYS and 
HOMOARG only.
IC50 and Ki values determination for LYS and HOMOARG. A full characterisation of the kinetic profile of argin-
ase 1 and arginase 2 inhibition by LYS and HOMOARG was performed. The derived IC50 and kinetic constants 
are reported in Table 4. Experimental data for the inhibition of arginase 1 and 2 by LYS and HOMOARG were 
poorly fit by the equations for uncompetitive, noncompetitive and mixed inhibition. By contrast, data fitted well 
with the equation for the competitive model. Fitted values and statistical descriptors are given in Table 4 and fitted 
models, plotted with experimental data, are shown in Figs 5 and 6.
HOMOARG as a substrate for arginase 1 or arginase 2. The formation of LYS as a potential product of 
the reaction of HOMOARG with arginase 1 and arginase 2 was determined by UPLC-MS. Extracted ion chroma-
tograms (EICs) were obtained with a mass window of 0.02 Da from total ion chromatograms (TIC) using m/z of 
147.13 corresponding to the parent ion ([M + H] +) for LYS. The retention time for LYS was 5.98 minutes as con-
firmed using pure LYS. LYS quantification was linear between 0 and 100 µM, with a limit of detection of 0.3 µM 
and a limit of quantitation of 1 µM (determined using a signal to noise ratio of 3:1 and 10:1, respectively) for the 
arginase 1 and arginase 2 assays. We could not detect the formation of LYS from HOMOARG in our experiments 
(data not shown).
Plasma homoarginine concentrations and arginine/ornithine ratio in humans. The median age 
of the study population was 70 years (IQR 67–73). Mean baseline plasma concentrations of HOMOARG, ARG, 
and ORN were 2.36 ± 0.76 µmol/L, 305 ± 44 µmol/L, and 87 ± 16 µmol/L, respectively, whereas the mean ARG/
ORN ratio was 3.58 ± 0.69. After adjusting for age, sex, and estimated glomerular filtration rate, there were no sig-
nificant correlations between plasma HOMOARG and ARG or ORN concentrations, and between HOMOARG 
Figure 4. Kinetic plots representing the conversion of ARG to ORN by arginase 1 (A and B) and by arginase 
2 (C and D). Each data point is the mean of three singlicate experiments and error bars represent the standard 
error. The data is represented as an Eadie-Hoffstee transform in B and D. The Michaelis-Menten fit is shown as a 
solid line in panel A and C.
www.nature.com/scientificreports/
6SCIentIFIC REpoRTS |  (2018) 8:3697  | DOI:10.1038/s41598-018-22099-x
concentrations and the ARG/ORN ratio. Similarly, there were no significant correlations between plasma LYS and 
the ARG/ORN ratio (Table 5).
Discussion
Here we investigated the inhibitory potential of HOMOARG on arginase enzyme activity using a newly devel-
oped, robust, sensitive, and highly selective UPLC-MS assay that measured ORN formation from recombinant 
human arginase 1 and arginase 2. Additionally, we investigated the hypothesis that HOMOARG serves as a sub-
strate of these enzymes. The effects of HOMOARG on arginase activity were compared to those of other endoge-
nous compounds serving either as negative (PRO, AG, ADMA, SDMA and L-NMMA) or positive (LYS) controls. 
Furthermore, we assessed the associations between plasma concentrations of HOMOARG and the ARG/ORN 
ratio in a cohort of healthy older adults without significant disease states and/or pharmacological treatment that 
may affect the outcomes of interest. In our study, HOMOARG showed significant inhibitory effects towards 
arginase 1 and 2 activity at concentrations that are considerably higher than those reported clinically in plasma 
(2.01 ± 0.67 µM) or in the cytoplasm (2.37 ± 2.28 µM) of peripheral blood mononuclear cells23. Furthermore, 
there were no significant associations between plasma HOMOARG concentrations and the ARG/ORN ration in 
the human study.
Several studies have recently reported an inverse correlation between HOMOARG plasma concentrations 
and the risk of cardiovascular events and overall mortality1–8. In some of these reports, arginase inhibition 
was proposed as a potential molecular mechanism accounting for the protective effect of HOMOARG in the 
Isoenzyme ARG Inhibitor
% of control activity at the corresponding [Inhibitor] ± SE
0.1 µM 1 µM 10 µM 100 µM 1,000 µM 10,000 µM
Arginase 1
3 mM
HOMOARG — 106 ± 7 110 ± 1 96 ± 6 86 ± 13 50 ± 1
LYS — 108 ± 13 103 ± 10 82 ± 4 63 ± 8 22 ± 1
PRO — 100 ± 1 113 ± 26 106 ± 19 100 ± 17 79 ± 20
AG — 84 ± 13 100 ± 3 100 ± 8 98 ± 13 78 ± 7
ADMA 98 ± 7 89 ± 2 90 ± 1 86 ± 4 69 ± 4 —
SDMA 113 ± 16 93 ± 5 92 ± 2 84 ± 1 73 ± 5 —
L-NMMA 106 ± 15 107 ± 11 95 ± 9 94 ± 8 97 ± 11 —
100 µM
HOMOARG — 112 ± 4 107 ± 4 85 ± 1 70 ± 1 24 ± 8
LYS — 88 ± 21 89 ± 10 105 ± 18 56 ± 5 19 ± 1
PRO — 115 ± 1 110 ± 1 110 ± 6 104 ± 3 54 ± 7
AG — 94 ± 7 82 ± 5 110 ± 24 84 ± 8 72 ± 3
ADMA 102 ± 9 109 ± 4 120 ± 12 109 ± 8 87 ± 1 —
SDMA 96 ± 3 113 ± 22 104 ± 4 106 ± 17 69 ± 10 —
L-NMMA 95 ± 2 91 ± 6 104 ± 11 95 ± 6 116 ± 1 —
Arginase 2
2 mM
HOMOARG — 95 ± 3 106 ± 2 94 ± 2 72 ± 1 15 ± 8
LYS — 88 ± 6 82 ± 6 84 ± 5 58 ± 1 33 ± 4
PRO — 98 ± 1 97 ± 7 96 ± 12 98 ± 10 75 ± 8
AG — 104 ± 4 96 ± 3 103 ± 3 96 ± 3 87 ± 8
ADMA 80 ± 7 84 ± 12 92 ± 12 90 ± 14 87 ± 15 —
SDMA 96 ± 2 100 ± 3 107 ± 1 102 ± 1 96 ± 1 —
L-NMMA 96 ± 7 105 ± 4 109 ± 8 104 ± 3 118 ± 4 —
100 µM
HOMOARG — 107 ± 2 105 ± 5 100 ± 5 53 ± 4 12 ± 5
LYS — 92 ± 6 97 ± 5 78 ± 11 56 ± 14 12 ± 4
PRO — 92 ± 10 99 ± 1 99 ± 2 92 ± 7 77 ± 16
AG — 103 ± 4 98 ± 7 92 ± 6 78 ± 5 58 ± 1
ADMA 115 ± 7 112 ± 13 109 ± 9 94 ± 14 104 ± 3 —
SDMA 90 ± 2 96 ± 1 95 ± 3 90 ± 1 89 ± 1 —
L-NMMA 101 ± 1 103 ± 2 106 ± 1 106 ± 9 111 ± 4 —
Table 3. Concentration-dependent inhibition of the conversion of ARG to ORN by arginase 1 and arginase 2. 
Each data point is the mean of two independent experiments.
Enzyme Inhibitor IC50 ( ± SE)/mM F-value R2 Ki ( ± SE)/mM F-value R2
Arginase 1
LYS 3.64 ± 0.20 1491 0.993 1.79 ± 0.01 1358 0.992
HOMOARG 8.14 ± 0.52 584 0.983 6.10 ± 0.50 1997 0.995
Arginase 2
LYS 0.88 ± 0.01 2028 0.995 0.50 ± 0.03 1268 0.991
HOMOARG 2.52 ± 0.01 1691 0.994 1.73 ± 0.10 4114 0.997
Table 4. Derived parameters for arginase 1 and arginase 2 inhibition by LYS and HOMOARG SE: standard error.
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cardiovascular system. NO is a key modulator of endothelial function and vascular homeostasis. By inhibiting 
arginase activity, HOMOARG would increase the availability of ARG as a substrate for NO synthase (NOS) and, 
therefore, NO availability1,7. While our in vitro data confirm the inhibitory potential of HOMOARG on both 
arginase 1 and arginase 2, the lack of significant inhibition at physiological concentrations questions the biological 
and clinical significance of arginase inhibition as a key mechanism accounting for the observed cardio-protective 
effects of HOMOARG. To determine if HOMOARG was acting as a substrate for arginase 1 or arginase 2 we 
investigated the formation of LYS as the product from the reaction, instead of ORN24. Increasing concentrations 
of HOMOARG did not result in increasing concentrations of LYS. Therefore, we propose HOMOARG is not a 
substrate of arginase 1 or arginase 2 under our experimental conditions.
Figure 5. Kinetic plots for arginase 1 and arginase 2 inhibition by LYS. Error bars represent the standard 
error of the mean. (A) Arginase 1 inhibition by LYS IC50 plot. Each data point is the mean of two singlicate 
experiments, (B) Arginase 1 inhibition by LYS Ki plot. Each data point is the mean of three singlicate 
experiments and the competitive model fit is represented as solid lines, (C) Representative Dixon plot of the 
inhibition of arginase 1 by LYS. Each data point is the mean of three singlicate experiments and the competitive 
model fit is shown as solid lines, (D) Arginase 2 inhibition by LYS IC50 plot. Each data point is the mean of 
two singlicate experiments, (E) Arginase 2 inhibition by LYS Ki plot. Each data point is the mean of three 
singlicate experiments and the competitive model fit is shown as solid lines, (F) Representative Dixon plot of the 
inhibition of arginase 2 by LYS. Each data point is the mean of three singlicate experiments and the competitive 
model fit is represented as solid lines.
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Numerous studies have reported the kinetic characterisation of arginase 1 and arginase 2 activity11–13,15,17,25,26. 
By and large, published methods adopted colorimetric techniques for measuring urea formation in enzymatic 
reactions with ARG utilised as the substrate. Despite the advantages of this approach, such as low costs and high 
sensitivity, there are also significant limitations, in particular, poor specificity and reproducibility. By using mass 
spectrometry to detect and measure ORN as a product of arginase activity, our assay benefits from the inher-
ent high selectivity and specificity of this technique. Another potential advantage of our approach is the use of 
un-purified protein in the form of EDTA-free lysates from HEK293T cells recombinantly expressing arginase 1 or 
arginase 2. This approach more closely mimics the in vivo environment by including the complexity of a cellular 
Figure 6. Kinetic plots for arginase 1 and arginase 2 inhibition by HOMOARG. Error bars represent the 
standard error of the mean. (A) Arginase 1 inhibition by HOMOARG IC50 plot. Each data point is the mean 
of two singlicate experiments, (B) Arginase 1 inhibition by HOMOARG Ki plot. Each data point is the mean 
of three singlicate experiments and the competitive model fit is represented as solid lines, (C) Representative 
Dixon plot of the inhibition of arginase 1 by HOMOARG. Each data point is the mean of three singlicate 
experiments and the competitive model fit is shown as solid lines, (D) Arginase 2 inhibition by HOMOARG 
IC50 plot. Each data point is the mean of two singlicate experiments, (E) Arginase 2 inhibition by HOMOARG 
Ki plot. Each data point is the mean of three singlicate experiments and the competitive model fit is shown as 
solid lines, (F) Representative Dixon plot of the inhibition of arginase 2 by HOMOARG. Each data point is the 
mean of three singlicate experiments and the competitive model fit is represented as solid lines.
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system. Furthermore, since our cellular lysates did not include chelating agents, and no purification steps were 
required to isolate the arginase 1 and arginase 2 proteins, manganese supplementation in kinetic experiments was 
not required. This allowed the use of phosphate buffer in the experimental system instead of “non-physiological” 
Tris-HCl. To demonstrate this point, we compared arginase activity in the presence and absence of manganese. 
Of particular note, we observed the rate of ORN formation was 20% higher in incubations undertaken in the 
absence of manganese, relative to samples in which 0.5 mM manganese chloride was supplemented to the incuba-
tion mixture. Despite the absence of manganese supplementation, the parameters derived from our experimental 
system were similar to those previously reported. For arginase 1 we determined the Km to be 3.3 ± 0.2 mM, which 
is within the range of 1–9 mM previously reported for arginase 110–13,18,27. Similarly, for arginase 2 the Km value 
was 1.9 ± 0.1 mM, which is within the range of 1–7 mM previously reported15,17,21,27.
The methylated arginines ADMA, SDMA and L-NMMA, chemical analogues of the substrate ARG and 
important modulators of the nitric oxide pathway, were confirmed as poor arginase inhibitors in agreement with a 
previous study18. Similarly, no significant inhibition was observed with PRO and AG. LYS reduced arginase 1 and 
arginase 2 activity by 37–42% and 67–78% at concentrations of 1 and 10 mM, respectively, when the inhibition 
experiments were conducted at the Km determined for ARG. A similar effect was observed at physiological ARG 
concentrations with 10 mM LYS inhibiting arginase 1 activity by 81% and arginase 2 activity by 88%. HOMOARG 
at concentrations of 1 and 10 mM was also effective in inhibiting arginase 1 and arginase 2 activity at concentra-
tions of 0.1 and 2 mM (Table 3).
A full kinetic characterisation of LYS and HOMOARG as arginase 1 and arginase 2 inhibitors was per-
formed and, consistent with the report of Ikemoto et al.12, the Ki values for arginase 1 inhibition by LYS and 
HOMOARG were found to be 1.8 and 6.1 mM, respectively (Ikemoto et al. reported Ki = 2.5–2.7 mM for LYS and 
Ki = 5.0–5.2 mM for HOMOARG). However, both LYS and HOMOARG exhibited a higher inhibitory potential 
on arginase 2 than previously reported, with IC50 and Ki values for LYS and HOMOARG of 0.9 and 0.5 mM 
(Colleluori et al. reported a Ki = 7 mM)15 and of 2.5 mM and 1.7 mM, respectively (Colleluori and Ash reported 
a Ki of 39 mM)17.
Similar to HOMOARG, none of the experiments performed showed inhibition of the arginase isoenzymes 
when LYS was used at concentrations close to the reported circulating values (276 ± 120 µM)22.
It is important to emphasise that the results of enzymatic studies in isolation cannot easily translate into the 
complexity of a living system and account for other related and/or competing enzymatic pathways28,29. However, 
when the experimental conditions are accurately chosen to match those present in vivo (particularly in terms of 
temperature, pH, buffer composition, and ionic strength), the findings can be used to speculate the physiological 
behaviour of the enzyme. Furthermore, good correlations are observed between in vitro kinetic experiments and 
in vivo Kcat using approaches that combine computational flux predictions and proteomics data30.
Using a cohort of healthy older adults, we further tested the hypothesis that plasma HOMOARG concen-
trations may be positively associated with the ARG/ORN ratio, a proposed indicator of arginase activity31. The 
lack of a significant correlation between HOMOARG concentrations and the ARG/ORN ratio in our study is in 
contrast to a previous study by Marz et al. that reported a significant positive correlation (r = 0.32; P =  < 0.001) 
in 3,305 subjects with high cardiovascular risk1. There are several significant differences between the two studies: 
1) the ARG/ORN ratio in our study (3.58 ± 0.69) is significantly higher than the ratio reported by Marz et al. 
(1.47 ± 0.42); (2) The study by Marz et al. included patients with diabetes and hypertension. Interestingly, both 
these conditions are associated, per se, with an increase in arginase activity;32,33 and perhaps most importantly, (3) 
our cohort includes only healthy subjects, while the LURIC cohort comprised individuals with different patho-
logical conditions, extremes of renal function and subjects undertaking different medications, all conditions that 
affect arginase activity34.
Although arginase inhibition is unlikely to be a key mechanism involved in the putative cardioprotective 
effects of HOMOARG, other mechanisms may play a role. For example HOMOARG is reported to be an alter-
native substrate for the enzyme NOS20,35, and despite its low affinity for the enzyme, it can directly increase NO 
availability1. Likewise, HOMOARG is a substrate of the different members of the cationic amino acid transporter 
(CAT) family of transporters and significantly inhibits the uptake of ARG by CAT-1, thus increasing ARG availa-
bility for NOS36. Furthermore, it may reduce blood pressure by facilitating the excretion of nitrate1,37.
In conclusion, HOMOARG-mediated arginase 1 and arginase 2 inhibition was observed at concentrations that 
are significantly higher than those observed in plasma or serum and in the cytoplasm. In support of this observa-
tion, there was no association between plasma HOMOARG and the ARG/ORN ratio in a cohort of healthy older 
adults. As such, arginase inhibition is unlikely to play a significant role in the protective effects of HOMOARG 
against cardiovascular risk and mortality.
Homoarginine Lysine Arginine Ornithine Arg/Orn
Homoarginine — r = 0.16 P = 0.31 r = 0.13 P = 0.38 r = −0.01 P = 0.92 r = 0.05 P = 0.73
Lysine r = 0.16 P = 0.31 — r = 0.30 P = 0.05 r = 0.26 P = 0.10 r = 0.02 P = 0.92
Arginine r = 0.13 P = 0.38 r = 0.30 P = 0.05 — r = 0.40 P = 0.007 r = 0.41 P = 0.006
Ornithine r = −0.01 P = 0.92 r = 0.26 P = 0.10 r = 0.40 P = 0.007 — r = −0.63 P < 0.001
Arg/Orn r = 0.05 P = 0.73 r = 0.02 P = 0.92 r = 0.41 P = 0.006 r = −0.63 P < 0.001 —
Table 5. Partial correlations, adjusted for age, sex, and estimated glomerular filtration rate, between plasma 
homoarginine, lysine, arginine, and ornithine concentrations, and the arginine/ornithine ratio (Arg/Orn)*. 
*n = 46.
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Methods
In vitro studies. The experimental protocols for the assessment of arginase 1 and 2 inhibition in vitro, 
described below, were approved by the Institutional Biosafety Committee of Flinders University (IBC No 2009-
08). All methods were performed in accordance with the relevant guidelines and regulations.
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
Materials
Deuterated L-ornithine (ORN-d6), NG, N′G-dimethyl-L-arginine dihydrochloride (SDMA), and L-NG- 
monomethyl arginine (L-NMMA) acetate were obtained from Sapphire Bioscience (Sapphire Bioscience, 
Redfern, Australia). High purity water was obtained using a MilliQ Synergy UV Ultrapure water system (Merck 
Millipore, Sydney, Australia). Acetonitrile (LC-MS Grade), 2-propanol and formic acid (HPLC Grade) were 
obtained from Merck Millipore (Merck Millipore, Melbourne, Australia). All other laboratory grade chemicals 
and reagents were purchased from Sigma-Aldrich (Sigma-Aldrich, Sydney, Australia).
Stock solutions of 1 M ARG, 100 mM ORN, LYS, PRO, AG, HOMOARG and 10 mM L-NMMA, SDMA and 
ADMA, together with a 1 mg/mL stock solution of ORN-d6 were prepared in purified water. These solutions were 
stored frozen at −20 °C. The working internal standard solutions were prepared by diluting the 1 mg/mL ORN-d6 
stock solution with water to 300 µM or 1200 µM final concentration. These working internal standard solutions 
were stored frozen at −20 °C.
Arginase 1 and arginase 2 cloning and expression. The C-terminal cMYC-FLAG-tagged human 
arginase 1 (NM_000045) and arginase 2 (NM_001172) coding sequences (CDS) were purchased from Origene 
(OriGene Technologies, Rockville, MD) and shuttled into the pEF-IRES(6) mammalian expression vector. Cells 
were transfected with the pEF-IRES-arginase 1 or with the pEF-IRES-arginase 2 expression constructs (4 μg) 
using Lipofectamine2000 in OptiMEM (Invitrogen, CA, USA). The stable expression of arginase 1 and arginase 2 
was achieved in HEK293T cells using puromycin as the selectable antibiotic.
A single batch of recombinant arginase 1 and arginase 2 was used in all experiments to avoid batch-related 
variability. Cultured cells were grown to 90% confluence, harvested, washed in phosphate-buffered saline solu-
tion and lysed by sonication in phosphate buffer (0.1 M, pH = 7.4) supplemented with an EDTA-free complete 
protease inhibitor cocktail (Roche Diagnostic GmbH, Mannheim, Germany) and 1 mM PMSF. Cell lysates were 
centrifuged for 10 minutes at 4 °C at 18000 xg to remove cellular debris and the supernatant fractions aliquoted 
to avoid repeated freeze thaw cycles and subsequently stored at −80 °C until use. Protein concentrations were 
determined by the method of Lowry38.
Western blot analysis. Sodium dodecyl sulfate (SDS)–polyacrylamide gel electrophoresis was performed 
on cell lysates using 10% acrylamide gels to separate the denatured protein (120 V), and then transferred to 
Trans-Blot® Transfer Medium pure nitrocellulose (BIORAD; 0.45 μm; 100 V). Membranes were blocked in 4% 
(w/v) non-fat milk in Tris-buffered saline Tween20 for 90 mins with the primary immunodetection of arginase 1 
and arginase 2 proteins achieved by probing blots with anti-arginase 1 (Santa Cruz, CA; 1:1000), anti-arginase 2 
(Santa Cruz, CA; 1:1000,), and anti-FLAG (Sigma-Aldrich, Sydney, Australia; 1:5000) antibodies. Subsequently, 
blots were incubated with the corresponding peroxidase conjugated secondary antibodies (1:2000, 1 hour), with 
immunoreactivity detected using the SuperSignalWest Pico Chemiluminescent (ECL) HRP substrate (Thermo 
Fisher Scientific, Victoria, Australia) and imaged using the ImageQuant LAS-400 image reader (Fujifilm, Japan).
Analytical instrumentation. ORN, LYS and ARG separation, detection and quantification were performed 
on a Waters ACQUITYTM Ultra Performance LC™ system coupled to a Waters Premier quadrapole time of flight 
(qToF) mass spectrometer (Waters, Sydney, Australia). The electrospray ionisation (ESI) source was operated in 
positive ionisation mode (V+) and data collected over 10 min in ToF MS mode between 50 and 1000 Da with 
an instrument scan time of 1 sec and inter-scan delay of 0.1 sec. The mass spectrometer parameters are shown in 
Table 6. Instrument control, data acquisition and data processing were performed using Waters MassLynx soft-
ware (version 4.1, Waters, Sydney, Australia).
UPLC-MS analysis of ORN. ORN was separated from the cellular lysate components on a Waters AtlantisTM 
HILIC column (2.1 × 150 mm, 3 µm, Waters, Sydney, Australia) held at 35 °C. The mobile phase comprised ace-
tonitrile containing 0.1% v/v formic acid (mobile phase A) and 0.1% formic acid in a solution of 10% v/v ace-
tonitrile in water (mobile phase B) at a flow rate of 0.4 mL/min. Initial conditions were 70% mobile phase A, 30% 
mobile phase B. The proportion of mobile phase B was increased linearly to 45% over 7.4 min, held at 45% for 
1 min then returned to 30% for 1.6 min to re-establish equilibrium prior to injection of the following sample.
The method was assessed for linearity, reproducibility and sensitivity (limit of detection and limit of quantita-
tion). Limit of quantitation was determined as the concentration of product giving 10:1 signal to noise ratio, while 
the limit of detection was assigned as the concentration corresponding to 3:1 signal to noise ratio. Calibration 
standards comprised of ORN concentrations ranging from 0 to 200 µM spiked into the incubation mixture and 
were extracted and reconstituted following the same procedure used for incubation samples.
Arginase activity assay. ORN formation was determined at 37 °C in a total incubation volume of 0.1 mL 
using 12 × 75 mm borosilicate glass tubes. Incubation mixtures contained HEK293T cell lysate expressing 
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recombinant human arginase 1 (0.05 mg/mL) or arginase 2 (0.1 mg/mL), phosphate buffer (0.05 M, pH 7.4) and 
ARG (0 to 15 mM).
Following a 5-min pre-equilibration period reactions were initiated by the addition of the cell lysate solution 
in 0.05 M phosphate buffer to a pre-equilibrated aqueous solution of the substrate (ARG). Following incubation 
at 37 °C the reaction was terminated by the addition of 300 μL 0.1% formic acid in 2-propanol and 10 µL of the 
assay internal standard ORN-d6 was added to each reaction tube. For the arginase 1 assay the incubation time 
was 10 min and the assay working internal standard solution was 1200 μM ORN-d6. For arginase 2 assays the 
incubation time was 20 min and the ORN-d6 working internal standard concentration was 300 μM
The samples were vortex mixed (20 sec) and cooled in an ice/water bath for 10 min prior to centrifugation 
(5 min, 18,000 × g, room temperature) to precipitate the proteins. An aliquot of the supernatant layer was diluted 
with a 7:3 mobile phase A/mobile phase B solution into glass UPLC vial inserts. For UPLC-MS analysis the argin-
ase 1 sample supernatant layer was diluted 1:20 with the mobile phase solution and 2 μL of each diluted sample 
was injected for ORN analysis whereas arginase 2 analysis was performed by diluting the supernatant layer 1:10 
and injecting 5 μL for analysis.
To determine if manganese supplementation was necessary, we performed an experiment using arginase 1 
(0.1 mg/mL), phosphate buffer (0.05 M, pH 7.4), ARG (0 to 10 mM) and manganese chloride (0 or 0.5 mM). 
Incubation samples were incubated for 20 min and protein was precipitated and samples prepared for ORN anal-
ysis as previously described.
Samples were maintained at 15 °C in the auto-sampler prior to analysis.
Arginase inhibition. Incubation mixtures comprised of HEK293T cell lysate expressing arginase 1 (0.05 mg/
mL) or arginase 2 (0.1 mg/mL), phosphate buffer (0.05 M, pH 7.4), inhibitor (0, 0.1, 1, 10, 100, 1000 or 10000 μM) 
and ARG (0.1, 2 or 3 mM). Following a 5-min pre-incubation of the potential inhibitor with arginase 1 or arginase 
2, reactions were initiated by the addition of a pre-equilibrated solution of the substrate ARG. Protein precipita-
tion and preparation for ORN analysis was performed as described above (see arginase activity assay).
IC50 experiments. For arginase 1 assay incubation mixtures comprised of arginase 1 cell lysate (0.05 mg/
mL), phosphate buffer (0.05 M, pH 7.4), LYS or HOMOARG (0–10 mM) and ARG (3 mM). Incubation, protein 
precipitation and preparation for ORN analysis were performed as previously described (see arginase inhibition 
and arginase activity assay).
For arginase 2 assay incubation mixtures comprised of arginase 2 cell lysate (0.1 mg/mL), phosphate buffer 
(0.05 M, pH 7.4), LYS (0–2.5 mM) or HOMOARG (0–5 mM) and ARG (2 mM). Incubation, protein precipita-
tion and preparation for ORN analysis were performed as described above (see arginase inhibition and arginase 
activity assay).
Ki experiments. For arginase 1 incubation mixtures comprised of arginase 1 cell lysate (0.05 mg/mL), phos-
phate buffer (0.05 M, pH 7.4), LYS or HOMOARG (0–10 mM) and ARG (0.6–15 mM). Incubation, protein pre-
cipitation and preparation for ORN analysis were performed as previously described (see arginase inhibition and 
arginase activity assay).
For arginase 2 incubation mixtures comprised of arginase 2 lysate (0.1 mg/mL), phosphate buffer (0.05 M, 
pH 7.4), LYS (0–2 mM) or HOMOARG (0–4 mM) and ARG (0.5–8 mM). Incubation, protein precipitation and 
preparation for ORN analysis was performed as described above (see arginase inhibition and arginase activity 
assay). Sample were diluted 3:17 in mobile phase solution prior injection.
In vivo studies
Homoarginine, lysine and arginine/ornithine ratio in humans. Plasma concentrations of 
HOMOARG, LYS, ARG, and ORN were measured, using an Aquity UPLC (Waters, Sydney, Australia) coupled to 
a qToF Premier high-resolution mass spectrometer (Waters, Sydney, Australia), in 50 healthy community dwell-
ing adults > 65 years (27 males and 23 females) participating in a study investigating the effects of fish oil con-
sumption on adaptations to resistance exercise39. Study participants had no previous history of significant disease 
and were not on regular medications, barring one female participant treated with angiotensin converting enzyme 
Instrument Parameter Setting
Capillary voltage (kV) 3.2
Sampling cone voltage (eV) 14.0
Extraction cone voltage (eV) 5.0
Source temperature (°C) 100
Desolvation temperature (°C) 300
Cone gas flow(L/Hr) 50.0
Desolvation gas flow (L/Hr) 400.0
Collision energy 3.0
Collision Cell Entrance 2.0
Collision Exit −10.0
Collision Gas Flow (mL/min) 0.6
Table 6. Mass spectrometer instrument settings.
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inhibitors for hypertension and one male participant treated with allopurinol for gout. The study was approved by 
the University of Aberdeen College of Life Sciences and Medicine Ethics Review Board (CERB/2011/6/644) and 
registered at clinicaltrials.gov (identifier NCT02843009). Each participant provided written informed consent 
prior to the study.
Data analysis. Kinetic constants (Km, Vmax) for ORN formation were derived from model fitting the 
Michaelis-Menten equation to experimental data using the nonlinear curve fitting software EnzFitter (version 
2.0.18.0: Biosoft, Cambridge, UK). Kinetic data are the mean of three singlicate experiments.
IC50 values for arginase 1 and arginase 2 inhibition by LYS and HOMOARG were determined by fitting the 
IC50 equation to experimental data using the same software and data are the mean of two singlicate experiments.
Fitting of the experimental data to noncompetitive, mixed and uncompetitive inhibition models was per-
formed using EnzFitter and comparison of the statistical values was used to determine the best fit. Ki values 
were derived from fitting the competitive inhibition equation to experimental data. Ki data are the mean of three 
singlicate experiments.
Goodness of fit of all equations was assessed from the F statistic, 95% confidence intervals, r2 value, and stand-
ard error of the parameter fit.
Associations between HOMOARG, ARG, and ORN concentrations, and ARG/ORN ratios in the human study 
were assessed by partial correlations, adjusted for age, sex, and estimated glomerular filtration rate. Analyses were 
performed using IBM SPSS Statistics Version 23, Release 23.0.0.2 (SPSS Inc., Armonk, NY, USA). A two-sided 
P < 0.05 indicated statistical significance.
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